General Information
Dear user
If you are in remission of ulcerative colitis, you can predict the relapse risk of your disease in the following year using this published calculation tool (1).
Please consult your doctor if you have the following conditions (2):
Fecal calprotectin>50 μg/g
Bowel movements per day>=8
Visible blood in the stool in more than 50% of the bowel movements and pass blood alone in>=1 bowel movement per day
Calculation:
For prediction of the relapse risk in the following year, enter the required information in the blanks (all fields marked with asterisks are required) and then click on "calculate". Therefore, you will find out how much at-risk you are for relapse. If you have a "Probability of relapse in one year">40%, you should consult your doctor to reduce the risk.
The related excel spreadsheet for risk score calculation is also available on calculator.xlsx
Clinical remission is characterized by the normal stool frequency, lack of bloody stool, and the pathology report of no active inflammatory activity in the previous three months.
Clinical relapse also is described as increasing bowel movement frequency (accompanied by intestinal bleeding) or deterioration of the abdominal pain and diarrhea, leading to change in previous treatment (increasing the dose, drug changes, and adding steroids), admission to hospital, or surgery.
References:
1. Hosseini SV, Safarpour AR, Taghavi SA. Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study. Pakistan journal of medical sciences. 2015 Nov;31(6):1511.
2. Clinical Review Report: adalimumab (Humira) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr. APPENDIX 5, Validity of Outcome Measures. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK539018/
Team
The present website is a tool for relapse risk prediction in patients with Ulcerative Colitis. This tool is based on a formula published in an ISI peer-reviewed journal and designed at Shiraz University of Medical Sciences by the following scientific working group:
Seyed Alireza Taghavi
MD, Subspecialty Board of gastroenterology & Hepatology
Professor of Gastroenterohepatology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, IranAli Reza Safarpour
MD, MPH, Ph.D. (Epidemiology)
Assistant Professor of Epidemiology, Gastroenterohepatology research center, Shiraz University of Medical Sciences, Shiraz, IranPeyman Jafari
M.Sc., Ph.D. (Biostatistics)
Professor of Biostatistics, School of Medicine Nanobiology and Nanomedicine Research Center, Shiraz University of Medical Sciences, Shiraz, IranSara Shojaei-Zarghani
M.Sc., Ph.D. (Nutrition)
Gastroenterohepatology research center, Shiraz University of Medical Sciences, Shiraz, IranReza Barati-Boldaji
M.Sc. (Nutrition)
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran